Hodson EL, Kranyak A, Salem I, Buckey JC Jr, et al.
Journal of tissue viability. Date of publication 2024 Aug 1;volume 33(3):449-451.
1. J Tissue Viability. 2024 Aug;33(3):449-451. doi: 10.1016/j.jtv.2024.06.001.
Epub 2024 Jun 5.
Adjunctive hyperbaric oxygen treatment for challenging pyoderma gangrenosum
cases.
Hodson EL(1), Kranyak A(2), Salem I(1), Buckey JC Jr(3).
Author information:
(1)Department of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH,
USA.
(2)Department of Dermatology, University of California San Francisco, San
Francisco, CA, USA. Electronic address: Allison.kranyak@ucsf.edu.
(3)Department of Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH,
USA; Center for Hyperbaric Medicine, Dartmouth-Hitchcock Medical Center,
Lebanon, NH, USA.
INTRODUCTION: Pyoderma gangrenosum (PG) is a rare, difficult-to-treat
neutrophilic ulcerative cutaneous condition that severely impacts those
affected. Treatment options for PG are limited, and disease remission is not
guaranteed. Hyperbaric oxygen treatment is a potential therapeutic option for
treating various ulcerative conditions not frequently utilized for PG.
CASE REPORT: We present a case of a patient with treatment-resistant PG who
achieved remission with adjunctive HBOT, and then later had difficulty achieving
remission without HBOT during a future flare.
DISCUSSION: HBOT should be more readily considered as a treatment option for
those with PG.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
DOI: 10.1016/j.jtv.2024.06.001
PMID: 38851917 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of competing interest All authors
have no relevant conflicts of interest to declare.
